References
1. Bhatia S, Landier W, Hageman L, et al. Systemic Exposure to
Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic
Leukemia: A Children’s Oncology Group Study. JAMA oncology.2015;1(3):287-295.
2. Vrooman LM, Blonquist TM, Harris MH, et al. Refining risk
classification in childhood B acute lymphoblastic leukemia: results of
DFCI ALL Consortium Protocol 05-001. Blood Adv.2018;2(12):1449-1458.
3. Bhatia S, Landier W, Hageman L, et al. 6MP adherence in a multiracial
cohort of children with acute lymphoblastic leukemia: a Children’s
Oncology Group study. Blood. 2014;124(15):2345-2353.
4. Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral
mercaptopurine and risk of relapse in Hispanic and non-Hispanic white
children with acute lymphoblastic leukemia: a report from the children’s
oncology group. J Clin Oncol. 2012;30(17):2094-2101.
5. US Census Bureau, American Community Survey. 2016.
6. Landier W, Hageman L, Chen Y, et al. Mercaptopurine Ingestion Habits,
Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children
With Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology
Group Study AALL03N1. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology.2017;35(15):1730-1736.
7. Landier W, Chen Y, Hageman L, et al. Comparison of self-report and
electronic monitoring of 6MP intake in childhood ALL: a Children’s
Oncology Group study. Blood. 2017;129(14):1919-1926.
8. Landier W, Hughes CB, Calvillo ER, et al. A grounded theory of the
process of adherence to oral chemotherapy in Hispanic and caucasian
children and adolescents with acute lymphoblastic leukemia. J
Pediatr Oncol Nurs. 2011;28(4):203-223.
9. Kahn JM, Athale UH, Clavell LA, et al. How Variable Is Our Delivery
of Information? Approaches to Patient Education About Oral Chemotherapy
in the Pediatric Oncology Clinic. J Pediatr Health Care.2017;31(1):e1-e6.